Price T Rowe Associates Inc Summit Therapeutics Inc. Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
A detailed history of Price T Rowe Associates Inc transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 2,042,100 shares of SMMT stock, worth $40.8 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,042,100
Previous 33,145
6061.11%
Holding current value
$40.8 Million
Previous $138,000
11443.48%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding SMMT
# of Institutions
146Shares Held
66.2MCall Options Held
1.05MPut Options Held
1.02M-
Baker Bros. Advisors LP New York, NY23.2MShares$464 Million2.41% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.82MShares$176 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$158 Million0.0% of portfolio
-
State Street Corp Boston, MA4.12MShares$82.3 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.96MShares$59.2 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $4.02B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...